Morgan Stanley lowered the firm’s price target on Qiagen to EUR 44 from EUR 47 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- QIAGEN N.V. to release results for Q2 2024 and hold webcast
- QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
- Dynatrace initiated, U.S. Bancorp downgraded: Wall Street’s top analyst calls
- Qiagen upgraded to Outperform from Peer Perform at Wolfe Research
- Qiagen price target raised to $54 from $52 at JPMorgan